Neither typical nor atypical: LY404039 provides proof of   concept that selective targeting of mGluR2/3 receptors is   a valid mechanism for obtaining antipsychotic efficacy.
Lebois
Evan P
EP
Vanderbilt University Medical Center, Department of Pharmacology, Nashville, TN 37232-6600, USA.
D014150:Antipsychotic Agents / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D003499:Cyclic S-Oxides / Q000494:pharmacology*; D006801:Humans; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
C517803:4-aminho-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid; D014150:Antipsychotic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003499:Cyclic S-Oxides; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3